Author: Hristopoulos, Maria ; Laing, Steven T. ; Lee, Genee ; Totpal, Klara ; Polson, Andrew G. ; Prell, Rodney A. ; Sukumaran, Siddharth ; Zhang, Crystal ; Lin, Kedan ; Dennis, Mark S. ; Mathieu, Mary ; Tam, Lucinda ; Stainton, Shannon ; Vuillemenot, Brian R. ; Gu, Chen ; Nguyen, Allen ; Newman, Robert ; Ellerman, Diego ; Lu, Elizabeth ; Leong, Steven R. ; Zheng, Bing ; Wong, Alfred ; Chu, Yu-Waye

Key PointsBispecific antibodies binding CD3 and CLL-1 deplete CLL-1+ target cells in animal models. An appropriately engineered CLL-1/CD3 bispecific antibody could be effective in treating AML.

01 Oct 2013·Clinical ImmunologyQ3 · MEDICINE

Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133high cancer stem cells in vitro and in vivo

Q3 · MEDICINE

Article

Author: Alfred E. Chang ; Haiyan Lv ; Yao Wang ; Hanren Dai ; Qiao Li ; Chonghui Li ; Yelei Guo ; Jianhua Huang ; Max S. Wicha

CD133 is a common marker of cancer stem cells (CSCs). We generated an anti-CD3/anti-CD133 bispecific antibody (BsAb) and bound it to the cytokine-induced killer (CIK) cells as effector cells (BsAb-CIK) to target CD133(high) CSCs. The killing of CD133(high) pancreatic (SW1990) and hepatic (Hep3B) cancer cells by the BsAb-CIK cells was significantly (p<0.05) higher than the killing by the parental CIK or by CIK cells bound with anti-CD3 (CD3-CIK) without CD133 targeting. In nude mice, the BsAb-CIK cells inhibited CD133(high) tumor growth significantly (p<0.05) more than that by CIK or CD3-CIK cells, or by the BsAb alone. BsAb-CIK cells co-cultured with CD133(high) cells produced significantly (p<0.05) higher amount of IFN-γ. Treatment with the BsAb-CIK cells significantly downregulated the expression of S100P and IL-18bp, but upregulated STAT1. The findings may help with the development of novel immunotherapies for patients with cancer containing CD133(high) CSCs by selectively targeting this cell population.

01 May 2008·Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

[The role of extracellular domain of human 4-1BBL in regulating activities of human peripheral blood lymphocytes in vitro].

Article

Author: Xu, Yuan-fu ; Fan, Dong-mei ; Yang, Chun-zheng ; Shao, Xiao-feng ; Su, Ye ; Cheng, Xin ; Xiong, Dong-sheng ; Guo, Hong-xing

AIMTo investigate the role of the extracellular domain of human 4-1BBL (ex4-1BBL) in regulating the in vitro activities of peripheral blood lymphocytes (PBL).METHODSViable cells were quantified with Trypan-blue exclusion assay. CytoTox 96 Nonradioactive Cytotoxicity Assay Kit was used for measuring LDH levels of supernatant. ELISA kit was used for measuring IL-2 level. In vitro cytotoxity of PBL combined with anti-CD3/anti-Pgp bispecific diabody plus ex4-1BBL was analyzed with CytoTox 96 nonradioactive method.RESULTSEx4-1BBL can increase the proliferation of PBL, reduce cell death, promote IL-2 secretion, and the experimental group with ex4-1BBL showed obviously enhanced cytotoxic effect toward K562/A02 cells.CONCLUSIONEx4-1BBL may be an important adjuvant for improving activities of PBL.

100 Deals associated with EX-105

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	IND Approval	CN	Excelmab, Inc.	15 Mar 2023
Pancreatic Cancer	Preclinical	CN	Excelmab, Inc.	30 Jan 2022
Pancreatic Cancer	Preclinical	US	Excelmab, Inc.	30 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

EX-105

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation